DLBCL_genes.md
... ...
@@ -91,7 +91,7 @@ link-citations: true
91 91
|[MEF2C](MEF2C)|Tier 1 GE[@arthurGenomewideDiscoverySomatic2018], FE[@jingjingNovelMEF2CMutation2020]|[Arthur et al](papers/arthurGenomewideDiscoverySomatic2018)|||
92 92
|[MGA](MGA)|Tier 1 GE[@reddyGeneticFunctionalDrivers2017], CE[@guoSGK1MutationStatus2022b]|[Reddy et al](papers/reddyGeneticFunctionalDrivers2017)|[@jalladesExomeSequencingIdentifies2017]||
93 93
|[MPEG1](MPEG1)|Tier 1 GE[@morinMutationalStructuralAnalysis2013], CE[@guoSGK1MutationStatus2022b]|[Morin et al](papers/morinMutationalStructuralAnalysis2013)|||
94
-|[MS4A1](MS4A1)|Tier 1 GE[@rushtonGeneticEvolutionaryPatterns2020]|[Rushton et al](papers/rushtonGeneticEvolutionaryPatterns2020)|[@mottokIntegrativeGenomicAnalysis2019b]||
94
+|[MS4A1](MS4A1)|Tier 1 GE[@rushtonGeneticEvolutionaryPatterns2020], FE[@rushtonGeneticEvolutionaryPatterns2020], CE[@rushtonGeneticEvolutionaryPatterns2020]|[Rushton et al](papers/rushtonGeneticEvolutionaryPatterns2020)|[@mottokIntegrativeGenomicAnalysis2019b]||
95 95
|[MTOR](MTOR)|Tier 1 GE[@zhangGeneticHeterogeneityDiffuse2013]|[Zhang et al](papers/zhangGeneticHeterogeneityDiffuse2013)|[@paneaWholeGenomeLandscape2019]||
96 96
|[MYC](MYC)|Tier 1 GE[@pasqualucciHypermutationMultipleProtooncogenes2001a], FE[@giallongoIdentificationCmycOncogene1983], CE[@christieCMYCTranslocation142008]|[Pasqualucci et al](papers/pasqualucciHypermutationMultipleProtooncogenes2001a)|[@dunsCharacterizationDLBCLPMBL2021b; @jalladesExomeSequencingIdentifies2017; @johnstonCmycHypermutationBurkitt1992]||
97 97
|[MYD88](MYD88)|Tier 1 GE[@ngoOncogenicallyActiveMYD882011a], FE[@ngoOncogenicallyActiveMYD882011a], CE[@guoSGK1MutationStatus2022b]|[Ngo et al](papers/ngoOncogenicallyActiveMYD882011a)|[@yanBCRTLRSignaling2012a]||
MS4A1.md
... ...
@@ -6,7 +6,10 @@ link-citations: true
6 6
# MS4A1
7 7
8 8
## Overview
9
-MS4A1 encodes the CD20 protein, which is the target of rituximab and other therapeutic monoclonal antibodies. MS4A1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been shown to reduce CD20 expression.<sup>1</sup>
9
+MS4A1 encodes the CD20 protein, which is the target of rituximab and other therapeutic monoclonal antibodies.
10
+MS4A1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas,
11
+which complicates the interpretation of mutations at this locus.
12
+In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been shown to reduce CD20 expression.[@rushtonGeneticEvolutionaryPatterns2020]
10 13
11 14
## History
12 15
```mermaid